Consensus Panel Recommendation for Incorporating Lipoprotein-Associated Phospholipase A2 Testing into Cardiovascular Disease Risk Assessment Guidelines
- 1 June 2008
- journal article
- review article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 101 (12) , S51-S57
- https://doi.org/10.1016/j.amjcard.2008.04.019
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Lipoprotein-Associated Phospholipase A2: An Independent Predictor of Coronary Artery Disease Events in Primary and Secondary PreventionThe American Journal of Cardiology, 2008
- Physician Knowledge of National Cholesterol Guidelines Before and After an Interactive CurriculumThe American Journal of Cardiology, 2007
- Glycoprotein Ibα Polymorphism T145M, Elevated Lipoprotein-Associated Phospholipase A2, and Hypertriglyceridemia Predict Risk for Recurrent Coronary Events in Diabetic Postinfarction PatientsDiabetes, 2007
- Optimal Medical Therapy with or without PCI for Stable Coronary DiseaseNew England Journal of Medicine, 2007
- Association Between Lipoprotein-Associated Phospholipase A2 and Cardiovascular Disease: A Systematic ReviewMayo Clinic Proceedings, 2007
- Lipoprotein-associated phospholipase A2 independently predicts the angiographic diagnosis of coronary artery disease and coronary deathAmerican Heart Journal, 2006
- Primary Prevention of Ischemic StrokeStroke, 2006
- Plasma markers of endothelial dysfunction in type 2 diabeticsEuropean Journal of Internal Medicine, 2006
- Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol LevelsNew England Journal of Medicine, 1998
- Probability of stroke: a risk profile from the Framingham Study.Stroke, 1991